Clinical Trial Update: Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma

View source ↗

Summary

This clinical trial update discusses Annexin A3 as a protein-based biomarker for non-invasive molecular diagnostics of prostate carcinoma, reported by ProteoSys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia
• Prostate Cancer
• Prostatic Intraepithelial Neoplasia

Snippet

Sponsor: ProteoSys AG | Conditions: Prostate Cancer, Benign Prostatic Hyperplasia | Status: UNKNOWN